Iluvien is Alimera’s sustained release intravitreal implant designed for the treatment of diabetic macular edema (DME). Currently, Iluvien is not approved for sale in Canada.
Iluvien (fluocinolone acetonide intravitreal implant) 0.19mg is a sustained release intravitreal implant approved in the US to treat DME in patients who have been previously treated with a course of corticosteroids and did not have a clinically significant rise in intraocular pressure.
As part of the deal, Knight will also be responsible for handling all regulatory and commercial activities for Iluvien in Canada.
Alimera president and CEO Dan Myers said: "We are excited to be working with Knight, whom we believe is well-positioned to assist us in obtaining regulatory approval for Iluvien in Canada and subsequently launching the product there.
"They are adept at introducing innovative products to the Canadian market, and we look forward to developing a successful partnership."
It is estimated that there are more than two million Canadians who have diabetes, about 2.5% of whom suffer from visual impairment due to DME.